The Roles and Mechanism of DHX34 Ablation in Enhancing Tumor Immunogenicity in Hepatocellular Carcinoma
Hongwei Tian,Chunli Zhang,Zeyu Li,Limin Huang,Yanhua Mu,Gaixia He,Jin Sun,Ting La,Guangyao Kong,Jing Geng,Zongfang Li
DOI: https://doi.org/10.1016/j.hpb.2023.07.381
IF: 17.298
2023-01-01
Hepatology
Abstract:Purpose: Tumor immunotherapy has achieved significant clinical efficacy in recent years, but only some patients respond to immunotherapy, mainly because the tumor microenvironment inhibits the anti-tumor immune response. DHX34 is one of the RNA helicases, and its role in the regulation of tumor immune microenvironment has not been studied. Method: We used CRISPR-Cas9, RNA-Seq sequencing, flow cytometry, co-immunoprecipitation, immunohistochemistry, immunofluorescence, and gene knockout mouse models to explore the function and specific mechanism of DHX34. Results: Analysis of the clinical database of liver cancer in the early stage showed that DHX34 was highly expressed in liver cancer, and was negatively correlated with patient survival, T cell infiltration, and inflammatory cytokines expression. We knocked out DHX34 expression in HepG2, which significantly promoted the expression of inflammatory factors in vitro, enhanced T cell activation and effector function, and significantly enhanced the anti-tumor effect in vivo. Mechanistic studies have shown that DHX34 knockout differential gene enrichment is in validating relevant pathways, mainly affecting type I interferon pathways. DHX34 knockout enhances the expression of ISG genes such as RIG-I, MDA-5, MAVS, and IFN-a, IFN-b, and overexpression of DHX34 partially inhibits or does not affect ISG gene expression. At the same time, knocking out DHX34 also enhanced the expression of chemokines such as CXCL9 and CXCL10, which contributed to immune cell infiltration into the tumor microenvironment. We also found that DHX34 knockout leads to the accumulation of endogenous dsRNA in cells, and excess dsRNA can induce the activation of the type I interferon pathway, leading to the expression of downstream effector factors, promoting the infiltration of inflammatory cells in the tumor microenvironment, and enhancing the anti-tumor immunity effect. Conclusion: Overall, this study elucidates the molecular mechanism by which DHX34 promotes tumor growth by reducing endogenous dsRNA accumulation and inhibiting type I interferon pathway activation. Inhibition or knockout of DHX34 significantly enhances the anti-tumor immune response. This study provides a theoretical basis for the development of DHX34 inhibitors to regulate the tumor immune microenvironment.